CD40 and neoplasm: Several interventions combining IL-15 agents with checkpoint inhibitors, antibodies stimulating immune cell functions (e.g., anti-CD40, anti-CD16), monoclonal antibodies specific for tumor-associated antigens, and immunotoxins have been tested in preclinical models, with promising results.